About US
Contact us
-
Indian regulators punch up standards as FDA action takes a toll on the industryTheFDAhas come down hard on some top Indian generic drugmakers in the last couple of years after realizing that they were cutting serious corners to get drugs to market. And while the infractions have2014/8/14
-
BMS, Pfizer marketing efforts have Eliquis showing signs of lifeEliquis, the third entrant in the next-gen anticoagulant market, got off to a sluggish start. But now, marketers Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) are pulling out all the stops when it com2014/8/13
-
New use for Bayer's Eylea in EU gives it more market power against Novartis' LucentisLast week, Regeneron ($REGN) announced that sales of its macular degeneration treatmentEyleajumped 26% to $415 million in the second quarter, blowing past analysts' estimates of $410 million. Now, its2014/8/12
-
Boehringer Ingelheim sees drug sales fall, says rest of the year will also be toughBoehringer Ingelheimis having a tough year with its drug business, seeing more than a 5% fall in sales in the first 6 months. The Germany-based company forecasts revenues will be down for the year as2014/8/12
-
Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar TecfideraBiogen Idec's ($BIIB) multibillion-sellingmultiple sclerosisdrugTecfiderais grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its2014/8/11
-
Pharma shares sink as U.S. threatens tax-inversion crackdownU.S. drugmakers have embraced the tax inversion strategy with open arms as of late, buying up foreign companies right and left and hauling overseas to take advantage of their lower rates. But U.S. off2014/8/8
-
Gilead Sciences prices Sovaldi in India at a tiny fraction of U.S. costThe $84,000 U.S. treatment price that Gilead Sciences ($GILD) is charging for itshepatitis CdrugSovaldihas elicited pleas from politicians and threats from payers, who say the U.S. healthcare system c2014/8/8
-
Sanofi enlists Emcure for cancer-drug marketing in IndiaSanofi ($SNY) hasn't wasted much time dithering in emerging markets. The company spent €39 billion on deals in emerging markets over the past four years. It now has 40 manufacturing sites in emergin2014/8/7
-
U.K. cost-effectiveness watchdog bars access to AstraZeneca's IressaBacktracking on a positive decision it made four years ago, Britain's National Institute for Health and Care Excellence (NICE) has dealt a blow to AstraZeneca ($AZN) by withdrawing its endorsement of2014/8/7
-
Roche persuades U.S. judge to toss $2M Accutane verdictRoche ($RHHBY) has emerged victorious in its quest to reverse a $2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne medAccutanefor her inflammatory bowel d2014/8/6